News

Heather O'Connell, PA-C, an allergy and asthma PA, describes how she uses clinical research and structured follow-up to shift patient thinking about the nose-lung connection, and why APPs bring a distinct advantage to that conversation.

Igudesman highlights satiety, diet quality, and macronutrients, among other endpoints, as important additional methods beyond weight loss for managing T1D.

Preview the biggest anticipated FDA decisions of Q3 2026, including atacicept for IgAN, mRNA flu vaccine, Furoscix ReadyFlow, and more.

O'Connell, an allergy and asthma PA, says the united airway concept has direct implications for how providers from different specialties recognize, refer, and communicate with one another about the same patient.

Real-world data highlight GLP-1 receptor agonist use with metreleptin in lipodystrophy and clinician guidance on timing and safety monitoring.

This episode covers the recent release of new data on Eledon’s tegoprubart for islet cell transplantation in patients with T1D.

A study from UC Berkeley has unveiled an AI model that outperforms standard clinical tests in identifying patients at risk of sudden cardiac death.

FDA approved risankizumab for children aged 6 years or older with plaque psoriasis or active psoriatic arthritis.

Leiter discusses the growth of incretin-based therapies through all aspects of the cardio-kidney-metabolic syndrome space.

Stay updated with the latest healthcare breakthroughs, including phase 3 data, new clinical findings, and regulatory updates.

At Maui Derm NP+PA Summer 2026, Matthew Zirwas, MD, shares cases of a factory worker with PPD allergy and a chronic spontaneous urticaria patient with persistent facial dermatitis.

Jessica Glennie, MSN, APRN, says the first formal ATS clinical guidelines on interstitial lung abnormalities are filling a real gap — but integration into practice is still catching up.

Leiter discusses the importance of earlier and more dramatic lipid-lowering interventions in patients with diabetes at risk of cardiovascular disease.

Lindsay Fourman, MD, discusses early real-world data exploring the use of GLP-1 receptor agonists alongside metreleptin in lipodystrophy.

Matthew Zirwas, MD, on why adult-onset atopic dermatitis is the most undertreated condition in dermatology and how diagnostic criteria are driving years of delayed care.

Dawn Eichenfield, MD, discusses off-label treatment rationale, biologics, JAK inhibitors, and care gaps in rare pediatric skin conditions.

With nerandomilast offering a more tolerable alternative to nintedanib and pirfenidone, Jessica Glennie, MSN, APRN, says the threshold for initiating antifibrotic therapy in early or stable disease is moving up.

Donna Culton, MD, PhD, explains why autoimmune blistering diseases often look nothing like the textbook and how to pursue the diagnosis anyway.

Igudesman discusses her presentation at ENDO 2026, during which she covered the importance of managing obesity with lifestyle changes in patients with T1D.

Stefan Weiss, MD, on recognizing mast cell disorders in the dermatology clinic and how avapritinib is reshaping treatment for indolent systemic mastocytosis.

The topic of precision medicine in dermatology is explored in this segment of Bunick's interview at RAD 2026.

Dawn Eichenfield, MD, PhD, discusses differential diagnosis, off-label treatment rationale, and multidisciplinary care for rare and atypical skin conditions in children.

This interview at RAD highlights FDA-approved therapies in the atopic dermatitis treatment armamentarium.

John Giacona, PhD, PA-C, says identifying pulmonary hypertension early, distinguishing its type, and engaging critically with clinical evidence are paramount.

Rishi Wadhera, MD, MPP, MPhil, addresses performance metrics, cross-specialty prescribing, and the policy forces reshaping the cardiometabolic care cascade.

The US FDA has approved olezarsen as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia.

Matthew Zirwas, MD, explains why topical JAK inhibitors represent a clinical turning point for hand eczema.

Rishi Wadhera, MD, MPP, MPhil, discusses where the cardiometabolic care cascade is failing most consequentially at the 10th Annual Heart in Diabetes Meeting.